Christopher B. Ehrlich, Partner, InterWest Partners

Mr. Ehrlich has served as a member of our board of directors since October 2004. He is currently a partner at InterWest Partners, a diversified venture capital firm, which he joined in August 2000. Before InterWest, Mr. Ehrlich was Director, Licensing & Business Development at Purdue Pharma, a private pharmaceutical firm based in Stamford, CT. Mr. Ehrlich worked in business development at Genentech, Inc., in venture capital at The U.S. Russia Investment Fund, and in biotechnology strategy development at LEK Consulting. He also currently serves on the boards of BioMimetic Pharmaceuticals, KAI Pharmaceuticals, Carbylan BioSurgery, Solace Pharmaceuticals, TransOral Pharmaceuticals and Xenon Pharmaceuticals. Mr. Ehrlich earned his Bachelor's degree from Dartmouth College, cum laude and an MBA from the J.L. Kellogg Graduate School of Management where he serves as an instructor and advisor to the Biotech Program.

Richard P. Fox

Mr. Fox has served as a member of our board of directors since January 2006. Since October 2001, Mr. Fox has served as a consultant and outside board member to entrepreneurs and the financial services industry. From April 2000 to September 2001, he was an officer of CyberSafe, an IT security company, serving as President and Chief Operating Officer from January 2001 to September 2001. Mr. Fox spent 28 years with Ernst & Young, last serving as Managing Partner of the Seattle office. He serves on the Board of Directors of Premera, a Blue Cross managed care provider, aQuantive, an on line marketing company, Flow International, a machine tool manufacturer, Isothermal Systems, and Shurgard Storage Centers, Inc. a real estate investment trust. In addition, he serves as Treasurer and is on the Board of Trustees of the Seattle Foundation and is on the Board of Visitors of the Fuqua School of Business, Duke University. Mr. Fox received a BBA degree from Ohio University and MBA from the Fuqua School of Business, Duke University. He is a Certified Public Accountant in Washington State.

Patrick Heron, Partner, Frazier Healthcare Ventures

Mr. Heron helped found QuatRx and has served as a member of our board of directors since our inception in November 2000. Through Frazier Healthcare Ventures, he was a founding investor in QuatRx. Mr. Heron has held various positions with Frazier Healthcare Ventures since September 1999, and is currently a general partner. Fraizer Healthcare Ventures manages venture capital funds that invest in early, mid and late stage biopharma, medical device and healthcare service companies. areas. Prior to Frazier Healthcare Ventures, Mr. Heron was with McKinsey & Co.'s biotechnology consulting practice from 1992 to 1999, working on corporate strategy, M&A, product launch, corporate partnering and research prioritization. Mr. Heron obtained a B.A. from, and was a Morehead Scholar at, the University of North Carolina at Chapel Hill and holds an M.B.A. from Harvard Business School. In addition to QuatRx, he also serves on the boards of Avera Pharmaceuticals, Chimerix, Cerexa Pharmaceuticals, Informed Medical Communication Panomics and Trubion Pharmaceuticals.

Anders Hove, M.D., General Partner, Venrock

Dr. Hove joined the QuatRx board in 2007. He has been with Venrock since 2004, applying his extensive knowledge in both venture capital and pharmaceutical operations to biotechnology companies at all stages. His experience in executive positions with the medical, clinical and business operations of the pharmaceuticals division of Ciba-Geigy led to his work as the CEO of Bellevue Asset Management. At Bellevue, Dr. Hove had responsibility for managing BB Biotech, an investment company with $1.6 billion invested in public and private companies, and he led numerous transactions in both. In addition to QuatRx, Dr. Hove also currently serves on the boards of Adnexus Therapeutics, AdvanDx, Alimera Sciences, Anacor Pharmaceuticals, PEAK Surgical and Trubion Pharmaceuticals. Dr. Hove received his M.Sc. in Biotechnology Engineering from the Technical University of Denmark, his M.D. from the University of Copenhagen and his M.B.A. from INSEAD.

Christopher Moller, Ph.D., Managing Director, TL Ventures

Dr. Moller has served as a member of our board of directors since December 2000 and, through TL Ventures, was a founding investor in QuatRx. In 1990, Dr. Moller joined Radnor Venture Partners, a TL Ventures predecessor fund, and has been leading the biotechnology group since 1992, having responsibility for selecting, evaluating and managing all the biotechnology companies in TL Ventures' portfolio. Dr. Moller currently serves as a director of Sopherion Therapeutics, PharmaStem Therapeutics and CombinatoRx. Dr. Moller holds a Ph.D. in immunology from the University of Pennsylvania.

Nicholas Simon III, Managing Director, Clarus Ventures and General Partner, MPM BioVentures III

Mr. Simon has served as a member of our board of directors since May 2003. Mr. Simon has been a Managing Director of Clarus Ventures, a life sciences focused venture capital firm, since February 2005. Mr. Simon has also been a General Partner in MPM Bioventures III since October 2001. From 2000 to July 2001, Mr. Simon was the Chief Executive Officer, founder and a director of Collabra Pharma, a pharmaceutical development company. From 1989 to March 2000, Mr. Simon served in various management positions with Genentech including Vice President of Business and Corporate Development. He currently serves on the board of directors of several biopharmaceutical companies, including ARYx Therapeutics, Barrier Therapeutics Inc. and CoTherix Inc., as well as several private companies. He also serves on the Advisory Board of Gladstone Foundation, a private not-for-profit research institute affiliated with UCSF. Mr. Simon holds a B.S. in microbiology from the University of Maryland and an M.B.A. from Loyola College.

Anders Wiklund

Mr. Wiklund has served on our board of directors since October 2005. Mr. Wiklund has been a principal of Wiklund International Inc., a biotechnology advisory firm, since January 1997, and serves on the boards of several other biopharmaceutical companies, including Medivir AB, EffRx, Gyros AB and Insite Vision Inc. Mr. Wiklund was also on the board and was a cofounder of Esperion Therapeutics. Previously, from January 1996 to December 1996, Mr. Wiklund led corporate business development at Pharmacia Inc. (later Pharmacia & Upjohn). Prior to that, Mr. Wiklund was chief executive officer and president of KabiVitrum Inc. and Kabi Pharmacia Inc., as well as president of KabiVitrum International in Stockholm, Sweden. Mr. Wiklund received his Masters of Pharmacy from the Pharmaceutical Institute in Stockholm, Sweden and studied business administration at the University of Stockholm.

Robert Zerbe, M.D., Chief Executive Officer, QuatRx

Dr. Zerbe co-founded QuatRx in November 2000 and has served as our Chief Executive Officer and President and as a member of our board of directors since inception. Dr. Zerbe has extensive experience in regulatory affairs and global clinical development at Eli Lilly in the United States and the United Kingdom, where he held a variety of research and development positions, including Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs, from 1982 to 1993. He joined Parke-Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development, during which time he oversaw the successful development programs for Lipitor, Neurontin and other key products. He serves on the boards of AP Pharma, Anesiva and Aastrom Bioscience. Dr. Zerbe earned his medical degree at Indiana University in 1975 and did post graduate training in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Mental Health.

Learn more about Who We Are by exploring the Management Team and the Board of Directors.